Calculate absolute eosinophil count from WBC and differential. Classify eosinophilia severity, review differentials, and get workup guidance by clinical context.
The Absolute Eosinophil Count (AEC) Calculator converts white blood cell count and eosinophil differential percentage into the absolute eosinophil count — the standard measure for classifying eosinophilia and guiding workup decisions. Eosinophils are granulocytes primarily involved in parasitic defense and allergic/inflammatory responses, normally comprising 1–5% of circulating white blood cells (100–500 cells/µL).
Eosinophilia is classified by severity: mild (500–1,500/µL, typically allergic or atopic causes), moderate (1,500–5,000/µL, suggesting parasitic infection, eosinophilic GI disease, or vasculitis), and severe/hypereosinophilia (>5,000/µL, requiring urgent evaluation for hypereosinophilic syndrome, eosinophilic leukemia, or end-organ damage). Even mild eosinophilia in the right clinical context (travel history, new medications, GI symptoms) warrants targeted investigation.
This calculator provides AEC computation from WBC + differential or direct input, severity classification using standard cutoffs, common differential diagnoses stratified by AEC level, and context-specific workup recommendations for allergy, GI, skin, travel, and hematologic presentations. Pediatric and neonatal reference ranges are included, as normal values differ from adults.
The relative eosinophil percentage can be misleading — a 5% eosinophil count with a WBC of 3.0 K/µL (AEC = 150, normal) is very different from 5% with a WBC of 20.0 K/µL (AEC = 1,000, moderate eosinophilia). The absolute count is essential for accurate classification and determines whether further workup is needed.
Absolute Eosinophil Count (AEC) = WBC (×10³/µL) × Eosinophil% / 100 × 1000 Result in cells/µL Normal range: 100–500 cells/µL (adults) Mild eosinophilia: 500–1,500 cells/µL Moderate eosinophilia: 1,500–5,000 cells/µL Severe eosinophilia: >5,000 cells/µL Neonatal normal: up to 1,000 cells/µL Pediatric normal: up to 700 cells/µL
Result: AEC: 960 cells/µL — Mild Eosinophilia
WBC 8.0 K/µL × 12% = 0.96 K/µL = 960 cells/µL. This falls in the mild eosinophilia range (500–1,500). In the absence of travel history, common causes include allergic rhinitis, asthma, eczema, or drug hypersensitivity. First-line workup: medication review, total IgE, allergen-specific testing if clinically indicated.
Step 1: Confirm with absolute count (not percentage). Step 2: Review medications — drug reactions are the most common remediable cause. Step 3: Travel and exposure history — helminthic infections are the most common cause worldwide. Step 4: Assess for allergic/atopic disease (IgE, skin testing). Step 5: Check stool O&P (×3), Strongyloides serology, Toxocara serology. Step 6: For persistent moderate-severe eosinophilia, evaluate for end-organ damage (echo, troponin, liver function, chest imaging). Step 7: If no etiology found, consider hematologic workup (peripheral smear, B12, tryptase, PDGFRA/FGFR1, bone marrow).
Pregnancy: mild eosinophilia is common and usually benign. HIV: eosinophilia may indicate drug reaction, adrenal insufficiency, or co-infection (Strongyloides, Toxocara). Transplant recipients: Strongyloides screening is mandatory before immunosuppression. Neonates: higher reference range (up to 1,000/µL) — consider congenital infections for persistent elevation.
Modern biologics targeting the eosinophilic pathway have transformed treatment: mepolizumab and reslizumab (anti-IL-5), benralizumab (anti-IL-5Rα), and dupilumab (anti-IL-4Rα) are approved for severe eosinophilic asthma, EGPA, and atopic dermatitis. These therapies dramatically reduce AEC (often to <100/µL) and improve clinical outcomes. They represent a paradigm shift from broad immunosuppression (corticosteroids) to targeted eosinophil depletion.
The most common causes vary by geography. In developed countries: allergic diseases (asthma, allergic rhinitis, eczema, food allergies), drug reactions, and eosinophilic GI diseases are most common for mild eosinophilia. For moderate eosinophilia: parasitic infections (especially tissue-invasive helminths), vasculitis (EGPA/Churg-Strauss), and adrenal insufficiency. For severe: hypereosinophilic syndrome, eosinophilic leukemia, and parasitic migration. Globally, helminthic infections are the most common cause overall.
HES is defined as persistent AEC >1,500/µL for ≥6 months with evidence of end-organ damage (cardiac, pulmonary, neurologic, skin, GI) caused by eosinophilic infiltration. It's a diagnosis of exclusion — secondary causes (parasites, drugs, allergy, malignancy) must be ruled out. Treatment: corticosteroids first-line, imatinib for FIP1L1-PDGFRA+, mepolizumab (anti-IL-5) for refractory cases.
With AEC >1,500: cardiac (endomyocardial fibrosis — echocardiogram, troponin), pulmonary (infiltrates, effusions — CXR, CT), skin (urticaria, angioedema), GI (eosinophilic infiltration — endoscopy), neurologic (neuropathy, encephalopathy), and hematologic (thrombosis). Cardiac involvement is the most life-threatening — it can occur silently.
DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) is a severe drug hypersensitivity reaction featuring eosinophilia >1,500/µL, fever, skin eruption, lymphadenopathy, and visceral organ involvement (liver most common). It typically occurs 2–8 weeks after drug initiation. Common culprits: allopurinol, anticonvulsants (carbamazepine, phenytoin, lamotrigine), antibiotics (vancomycin, minocycline), and dapsone.
Eosinopenia (AEC <100/µL) is common and usually benign. It's seen in: acute infections (eosinophils migrate to tissues), physical or emotional stress (cortisol effect), Cushing syndrome, and corticosteroid administration. Eosinopenia during acute illness is expected and doesn't require specific workup. Paradoxically, very low eosinophils during sepsis may be a marker of illness severity.
Bone marrow biopsy is indicated for: severe persistent eosinophilia (>5,000/µL), suspected HES or eosinophilic leukemia, abnormal peripheral smear (blasts, dysplasia), elevated B12 or tryptase, or eosinophilia unresponsive to corticosteroids. It evaluates for myeloid neoplasm, FIP1L1-PDGFRA fusion, and clonal T-cell populations that can drive reactive eosinophilia.